Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 8/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2841105 | 0.88 | IMPDH2 (0.41) | IMPDH2IMPDH1ARDRD2DRD1 | |
| SCHEMBL2839422 | 0.83 | MEN1 (0.39) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL2837042 | 0.78 | SIGMAR1 (0.36) | HCRTR1HCRTR2CYP3A4DRD1DRD5 | |
| SCHEMBL2835927 | 0.77 | IMPDH2 (0.38) | IMPDH2IMPDH1ARCYP3A4NPY1R | |
| SCHEMBL2838274 | 0.73 | SIGMAR1 (0.34) | — | |
| SCHEMBL2835969 | 0.73 | IMPDH2 (0.40) | IMPDH2IMPDH1AR | |
| Hydrochloric Acid SCHEMBL2841784 | 0.71 | IMPDH2 (0.41) | IMPDH2IMPDH1ARCYP3A4DRD2 | |
| SCHEMBL2845609 | 0.70 | MEN1 (0.41) | DRD2DRD1DRD4DRD5 | |
| SCHEMBL2844559 | 0.69 | OPRD1 (0.37) | HCRTR1HCRTR2CYP3A4ALDH1A1 | |
| SCHEMBL2841690 | 0.69 | OPRD1 (0.40) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217031-B2 | Heteroaryl derivatives | NIPPON SHINYAKU CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100048537-A1 | HETEROARYL DERIVATIVES | NIPPON SHINYAKU CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2141168-A1 | HETEROARYL DERIVATIVES | Nippon Shinyaku Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048537-A1 | HETEROARYL DERIVATIVES | OPRD1, OPRM1, OPRK1 | IMPDH2 3366/4885IMPDH1 2978/4885AR 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.